Primary Hepatic Anaplastic Large-Cell Lymphoma of T-cell Phenotype in Acquired Immunodeficiency Syndrome: A Report of an Autopsy Case and Review of the Literature

Baschinsky, Dmitry Y.; Weidner, Noel; Baker, Peter B.; Frankel, Wendy L.
January 2001
American Journal of Gastroenterology;Jan2001, Vol. 96 Issue 1, p227
Academic Journal
Anaplastic large-cell lymphomas (ALCL) were first described by Stein et al, in 1985 as large-cell neoplasms with a pleomorphic appearance, subtotal effacement of the lymph node structure, and expression of the lymphoid activation antigen CD-30 (Ki-I). Since their first description, these tumors have been documented in a variety of extranodal sites. We report a primary hepatic anaplastic large-cell lymphoma in a patient with advanced AIDS, who presented with hepatic failure and multiple nodules in the liver. A complete autopsy showed discrete tumor nodules throughout the entire liver without gross or microscopic involvement of lymph nodes or any other organs by the neoplastic process. The tumor cells showed typical histological and immunohistochemical features of ALCL and were strongly immunoreactive with the T-cell markers CD-3 and UCHL-1. Only one previous case of primary hepatic ALCL has been reported in the literature, and this tumor occurred in an immunocompetent patient and was not immunoreactive for B- or T-cell markers. To our knowledge, this study represents the first reported case of primary hepatic anaplastic large-cell lymphoma of T-cell phenotype. Additionally, this is the first case of primary hepatic ALCL reported in an AIDS patient.


Related Articles

  • Anti-CD20-based therapy of B cell lymphoma: state of the art. Kosmas, C.; Stamatopoulos, K.; Stavroyianni, N.; Tsavaris, N.; Papadaki, T. // Leukemia (08876924);Oct2002, Vol. 16 Issue 10, p2004 

    Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotopelabeled murine anti-CD20 MAbs are currently employed with...

  • Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Ciesielski, Michael J.; Ahluwalia, Manmeet S.; Munich, Stephan A.; Orton, Molly; Barone, Tara; Chanan-Khan, Asher; Fenstermaker, Robert A. // Cancer Immunology, Immunotherapy;Aug2010, Vol. 59 Issue 8, p1211 

    Survivin is a tumor-associated antigen with significant potential as a cancer vaccine target. We have identified a survivin peptide mimic containing human MHC class I epitopes and a potential class II ligand that induces a potent antitumor response in C57BL/6 mice with GL261 cerebral gliomas....

  • Ovarian follicular lymphoma: a case report and review of the literature. Niitsu, Nozomi; Nakamine, Hirokazu; Hayama, Miyuki; Unno, Yumi; Nakamura, Shigeo; Horie, Ryouichi; Iwabuchi, Keiichi; Nakamura, Naoya; Miura, Ikuo; Higashihara, Masaaki // Annals of Hematology;Nov2002, Vol. 81 Issue 11, p654 

    Primary ovarian lymphoma is extremely rare, and such a case is reported here. The patient was a 54-year-old Japanese female with abnormal genital bleeding. Pelvic CT and MRI showed a right ovarian tumor with a diameter of 7 cm and an irregular border. With the diagnosis of a right ovarian tumor,...

  • Intravascular Large B Cell Lymphoma: An Elusive Cause of Pyrexia of Unknown Origin Diagnosed Postmortem. Holmes, N. E.; Gordon, C. L.; Lightfoot, N.; Crowley, P.; Buchanan, R. R.; Smith, C. L.; Johnson, P. D. R. // Clinical Infectious Diseases;11/1/2010, Vol. 51 Issue 9, pe61 

    Intravascular large B cell lymphoma (IVLBCL) is a rare cause of pyrexia of unknown origin. Because of its protean clinical manifestations, diagnosis is elusive and is often made postmortem. We report here a case of IVLBCL that evaded diagnosis despite multiple investigations in vivo for pyrexia...

  • Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP. Bushway, Meghan; Cycon, Kelly A.; Mulvaney, Kathleen; Murphy, Shawn P. // Immunogenetics;Feb2010, Vol. 62 Issue 2, p109 

    Loss of major histocompatibility complex class II (MHCII) antigen expression on diffuse large B cell lymphoma (DLBCL) corresponds closely with significant decreases in patient survival. However, the mechanisms accounting for MHCII loss in DLBCL have not been thoroughly characterized to date. In...

  • RADIOIMMUNOTHERAPY ADVANCING. Kheyfits, Arkadiy // Radiology Today;Nov2010, Vol. 11 Issue 11, p32 

    The article discusses the treatment of follicular B-cell non-Hodgkin's lymphoma using two radioimmunotherapy (RIT) treatments, Zevalin and Bexxar. RIT has been developed as a targeted option for treating diffuse disease by linking radioactive isotopes to antigens created to bind a receptor on...

  • CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. Assaf, Chalid; Gellrich, Sylke; Whittaker, Sean; Robson, Alistair; Cerroni, Lorenzo; Massone, Cesare; Kerl, Helmut; Rose, Christian; Chaff, Andreas; Chimenti, Sergio; Hallermann, Christian; Petrella, Tony; Wechsler, Janine; Bagot, Martine; Hummel, Michael; Bullani-Kerl, Katrin; Bekkenk, Marcel W.; Kempf, Werner; Meijer, Chris J. L. M.; Willemze, Rein // Journal of Clinical Pathology;Sep2007, Vol. 60 Issue 9, p981 

    Background: Cutaneous lymphomas expressing CD56, a neural cell adhesion molecule, are characterised in most cases by a highly aggressive clinical course and a poor prognosis. However, prognostic subsets within the CD56+ group have been difficult to identify due to the lack of uniform...

  • Proteasome inhibition enhances HLA-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Stockmeyer, B.; Gramatzki, M.; Repp, R. // Cancer Cell International;2004 Supplement 1, Vol. 4, pS21 

    The article shows that proteasome inhibition enhances human leukocyte antigen (HLA)-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Although polymorphonuclear granulocytes (PMN) mediated significant lysis with HLA-class-II mAb, no significant...

  • B-cell receptor signaling derailed in lymphomas. Klein, Ulf; Pasqualucci, Laura // Immunology & Cell Biology;May/Jun2010, Vol. 88 Issue 4, p346 

    In this article the authors discuss the study about B-cell receptor (BCR). They state that an antigen that triggers the BCR provides a critical growth signal in the multistep process of lymphomagenesis as based on the characteristics of the reaaranged immunoglubin genes expressed by the tumor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics